Carbamoylated enzyme reversal as a means of predicting pyridostigmine protection against soman. [electronic resource]

By:

Ellin, R I

Contributor(s):

Kaminskis, A

Producer: 19900108Description: 633-6 p. digitalISSN:

0022-3573

Subject(s):

Acetylcholinesterase -- blood
Animals
Erythrocytes -- enzymology
Guinea Pigs
Half-Life
Haplorhini
Humans
Indicators and Reagents
Kinetics
Pyridostigmine Bromide -- pharmacology
Rabbits
Rats
Soman -- antagonists & inhibitors

Online resources:

Available from publisher's website

In: The Journal of pharmacy and pharmacology vol. 41

Tags from this library: No tags from this library for this title. Log in to add tags.

Star ratings

Cancel rating. Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes ( 1 )
Comments ( 0 )

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

Browse results Close

Back to results

1 Epothilones in breast cancer: review of clinical experience.
by Fornier, M N
2 Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.
by Cadoo, K A
3 Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
by Fornier, M N
4 Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
by Fornier, M N
5 Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
by Fornier, M N
6 A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
by Fornier, M N
7 Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
by Seidman, A D

Carbamoylated enzyme reversal as a means of predicting pyridostigmine protection against soman.

APA

Ellin R. I., Kaminskis A., . (19900108). Carbamoylated enzyme reversal as a means of predicting pyridostigmine protection against soman. : The Journal of pharmacy and pharmacology.

Chicago

Ellin R I, Kaminskis A, . 19900108. Carbamoylated enzyme reversal as a means of predicting pyridostigmine protection against soman. : The Journal of pharmacy and pharmacology.

Harvard

Ellin R. I., Kaminskis A., . (19900108). Carbamoylated enzyme reversal as a means of predicting pyridostigmine protection against soman. : The Journal of pharmacy and pharmacology.

MLA

Ellin R I, Kaminskis A, . Carbamoylated enzyme reversal as a means of predicting pyridostigmine protection against soman. : The Journal of pharmacy and pharmacology. 19900108.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Simple DC-RDF

OAI-DC

SRW-DC